XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value Measurements (Tables)
 6 Months Ended
Jun. 25, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

June 25,
2021
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$36.8 $23.4 $13.4 $— 
Equity securities
45.7 45.7 — — 
$82.5 $69.1 $13.4 $— 
Liabilities:
Deferred compensation liabilities
$34.1 $— $34.1 $— 
Contingent consideration and acquired contingent liabilities
29.2 — — 29.2 

$63.3 $— $34.1 $29.2 
December 25,
2020
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts$33.0 $23.5 $9.5 $— 
Equity securities31.1 31.1 — — 
$64.1 $54.6 $9.5 $— 
Liabilities:
Deferred compensation liabilities$38.0 $— $38.0 $— 
Contingent consideration and acquired contingent liabilities34.7 — — 34.7 
$72.7 $— $38.0 $34.7 
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the activity for contingent consideration:
Balance as of December 25, 2020$34.7 
Fair value adjustments
(5.5)
Balance as of June 25, 2021$29.2 
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
June 25, 2021December 25, 2020
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
5.75% senior notes due August 2022$610.3 $415.5 $610.3 $191.2 
4.75% senior notes due April 2023133.7 29.1 133.7 11.1 
5.625% senior notes due October 2023514.7 352.7 514.7 158.9 
5.50% senior notes due April 2025387.2 264.5 387.2 115.4 
10.00% first lien senior notes due April 2025495.0 551.2 495.0 528.4 
10.00% second lien senior notes due April 2025322.9 325.1 322.9 279.0 
Revolving credit facility900.0 900.0 900.0 900.0 
Level 2:
9.50% debentures due May 202210.4 — 10.4 4.2 
8.00% debentures due March 20234.4 — 4.4 1.3 
Term loan due September 20241,407.6 1,362.3 1,505.2 1,386.9 
Term loan due February 2025373.6 361.5 399.5 367.9 
Total Debt$5,159.8 $4,561.9 $5,283.3 $3,944.3 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total segment net sales. which excludes the one-time charge incurred during the three and six months ended June 26, 2020 related to the Medicaid lawsuit:
Three Months EndedSix Months Ended
June 25,
2021		June 26,
2020		June 25,
2021		June 26,
2020
CuraScript, Inc.
23.7 %30.2 %24.4 %27.5 %
The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
June 25,
2021		December 25,
2020
AmerisourceBergen Corporation
34.8 %33.6 %
McKesson Corporation
17.7 18.2 

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge incurred during the three and six months ended June 26, 2020 related to the Medicaid lawsuit:
Three Months EndedSix Months Ended
June 25,
2021		June 26,
2020		June 25,
2021		June 26,
2020
Acthar Gel27.7 %30.5 %25.4 %27.9 %
INOmax19.4 22.1 21.7 21.7 
Therakos12.5 *12.3 *
*Net sales attributable to these products were less than 10.0% of total net sales during the respective periods presented above.